#AACR17 roundup: Bris­tol-My­ers, Mer­ck KGaA and Pfiz­er in the spot­light, mark­ing progress with check­points

PHO­TO: © AACR/Todd Buchanan 2017

Bris­tol-My­ers IDs a sub­set of pa­tients who see a durable, 5-year re­sponse to Op­di­vo

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.